Skip to main content

Table 3 Association between HR status of first breast cancer and CBC risk, by time since diagnosis

From: Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

 

Time <5 years to CBC

Time 5 to <10 years to CBC

Time ≥10 years to CBC

 

N (cases/controls)

RRa (95% CI)

N (cases/controls)

RRa (95% CI)

N (cases/controls)

RRa (95% CI)

P-heterogeneity

All women, tumor status at first diagnosis

 ER status

  Positive

306/585

1.0 (ref.)

293/440

1.0 (ref.)

198/229

1.0 (ref.)

 

  Negative

186/241

1.4 (1.1, 1.9)

186/209

1.3 (1.0, 1.8)

95/111

1.0 (0.7, 1.5)

0.37

  Other/unknownb

94/160

 

95/155

 

68/82

  

 PR status

  Positive

262/477

1.0 (ref.)

249/395

1.0 (ref.)

176/211

1.0 (ref.)

 

  Negative

183/238

1.3 (1.0, 1.8)

169/203

1.3 (1.0, 1.8)

90/108

0.9 (0.6, 1.4)

0.26

  Other/unknownb

141/271

 

156/206

 

95/103

  

 Joint ER/PR status

  ER+/PR+

239/423

1.0 (ref.)

219/351

1.0 (ref.)

163/184

1.0 (ref.)

 

  ER+/PR-

38/68

1.0 (0.6, 1.6)

31/48

1.2 (0.7, 2.2)

16/26

0.6 (0.3, 1.3)

 

  ER-/PR-

145/166

1.5 (1.1, 2.1)

136/145

1.5 (1.0, 2.0)

71/76

1.1 (0.7, 1.6)

0.45

  Other/unknownb,c

164/329

 

188/260

 

111/136

  

Women who did not receive tamoxifen treatment for first diagnosis, tumor status at first diagnosis

 ER status

  Positive

169/290

1.0 (ref.)

141/196

1.0 (ref.)

97/108

1.0 (ref.)

 

  Negative

169/212

1.4 (0.9, 2.1)

166/173

1.4 (0.9, 2.0)

87/92

1.1 (0.7, 1.9)

0.77

  Other/unknownb

85/142

 

80/135

 

60/77

  

 PR status

  Positive

135/222

1.0 (ref.)

117/165

1.0 (ref.)

84/102

1.0 (ref.)

 

  Negative

159/187

1.4 (0.9, 2.1)

145/160

1.3 (0.8, 2.0)

82/82

1.3 (0.7, 2.2)

0.97

  Other/unknownb

129/235

 

125/179

 

78/93

  

 Joint ER/PR status

  ER+/PR+

121/185

1.0 (ref.)

97/136

1.0 (ref.)

75/83

1.0 (ref.)

 

  ER+/PR-

24/31

1.3 (0.6, 2.7)

16/26

0.7 (0.3, 2.0)

12/13

1.6 (0.4, 6.2)

 

  ER-/PR-

135/152

1.4 (0.9, 2.3)

127/125

1.5 (0.9, 2.4)

67/64

1.3 (0.7, 2.4)

0.84

  Other/unknownb,c

143/276

 

147/217

 

90/117

  
  1. Abbreviations: HR hormone receptor, CBC contralateral breast cancer, RR risk ratio, CI confidence interval, N number, ER estrogen receptor, PR progesterone receptor
  2. aAdjusted for age at first breast cancer diagnosis, first-degree family history of breast cancer, histologic assessment, stage, menopausal status, age at menarche, parity, radiation, chemotherapy and hormone therapy at first breast cancer diagnosis. b“Other/unknown” category consists of women for whom no laboratory test was given, the test was given and the results were unknown or the test was given and the results were borderline; estimates not reported. cIncludes tumors classified as ER-/PR+
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us